Core Viewpoint - The Hong Kong Innovative Drug ETF (513120) experienced a slight decline of 0.22% on November 27, with a trading volume of 5.444 billion yuan, indicating ongoing market activity and interest in innovative pharmaceuticals [1] Group 1: Fund Performance - The fund's total shares increased by 1.5 million, bringing the total to 18.681 billion shares, with a notable increase of 1.337 billion shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 25.505 billion yuan [1] - Since its inception on July 1, 2022, the fund has achieved a return of 36.52%, with a return of 0.41% over the past month [1] Group 2: Management and Benchmark - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - The performance benchmark for the fund is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1]
11月27日港股创新药ETF（513120）份额增加150.00万份
Xin Lang Cai Jing·2025-11-28 01:05